Jan. 10 at 2:15 PM
$ACRS The unique biparatopic binding architecture of ATI-045 confers exceptionally high affinity and an extended target residence time (~402 hours, best in class ), translating into strong potency and unexpected efficacy in treating AD. ATI-052, a bispecific antibody targeting TSLP and IL-4R, preserves this same biparatopic design, enabling potent and simultaneous blockade of TSLP-, IL-4–, and IL-13–mediated signaling. I believe this differentiated mechanism positions ATI-052 as a highly competitive, and potentially superior drug candidate to Pfizer’s trispecific TSLP/IL-4/13 antibody, even though I haven't seen the PK and PD data from Pfizers drug.
